Revenue segments as reported by the company.

Cardiovascular

Medical Surgical

Neuroscience

Diabetes

Other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general, and administrative

Amortization of intangible assets

Restructuring charges, net

Certain litigation charges, net

Other operating expense, net

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Medtronic

Medtronic Plc is a medical technology company, which engages in the development, manufacture, distribution, and sale of device-based medical therapies and services. It operates through the following segments: Cardiovascular Porrtfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment includes products for the diagnosis, treatment, and management of cardiac rhythm disorders and cardiovascular disease. The Neuroscience Portfolio is made up of cranial and spinal technologies, specialty therapies, and neuromodulation divisions. The Medical Surgical Portfolio is comprised of surgical innovations and respiratory, gastrointestinal, and renal divisions. The Diabetes Group segment offers insulin pumps, continuous glucose monitoring systems, and insulin pump consumables. The company was founded in 1949 and is headquartered in Dublin, Ireland.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Medtronic reports strong Q4 results, anticipates margin pressures for FY '24

MDT reported strong Q4 results with organic revenue growth, but anticipates margin pressures and EPS decline for FY '24. They highlighted successful FDA approvals and expressed confidence in growth opportunities.

Medtronic reports strong Q2 earnings, highlights growth opportunities

Medtronic's Q2 earnings call showcased strong financial performance, with raised full-year guidance. The company emphasized growth in key business segments and highlighted opportunities in insulin-dependent patient solutions and AI-powered solutions. Challenges include delays in PMRI spend and minimal impact of GLP-1s on the business.

Medtronic exceeds Q3 expectations, focuses on growth and transformation

Medtronic's Q3 earnings call highlighted strong performance, raised outlook, and a focus on transformation for sustainable growth. The company is strategically addressing challenges through cost reduction efforts and seizing opportunities in key markets. Medtronic remains committed to driving innovation and maximizing shareholder value.

Medtronic exceeds Q4 expectations, eyes growth in innovative healthcare

Medtronic's Q4 performance showcased strong growth in key segments, with a focus on innovation and market expansion. Despite challenges from inflation and currency impact, the company remains optimistic about future growth opportunities driven by product advancements and strategic acquisitions.

Medtronic reports robust Q1 results, eyes growth amid challenges

Medtronic's Q1 performance showcased strong revenue growth and emphasized innovation across key business segments.
While facing challenges of growth deceleration and margin expansion, the company remains focused on operational efficiencies and market fundamentals.
Opportunities lie in bariatric space growth, ongoing transformation efforts, and advancements in diabetes programs and surgical systems.
Overall, Medtronic's strategic investments in technology, pricing strategies, and procedural trends position it for continued success and market leadership.

Medtronic surpasses revenue expectations, eyes growth in key markets

Medtronic delivered strong Q2 results with revenue growth ahead of expectations and raised full-year guidance. Despite concerns about GLP-1 drugs and the SELECT trial, the company remains optimistic about growth prospects, focusing on key markets and product innovation.

Medtronic reports solid Q3 growth, focuses on innovation and profitability

Medtronic's Q3 earnings call showcased strong financial performance, international market growth, and strategic decisions to drive innovation and profitability. The company's focus on new technologies, portfolio management, and overcoming challenges highlights a path towards sustained growth and earnings leverage. With positive progress in key business segments and a commitment to future profitability, Medtronic is well-positioned for continued success.

Medtronic reports robust Q4 growth, eyes operational efficiency and China

Medtronic's Q4 2024 earnings call highlighted strong revenue growth, new product launches, and a focus on restoring earnings power. The company provided guidance for fiscal year '25, expecting organic revenue growth, operating margin expansion, and non-GAAP diluted EPS. Analyst questions centered on EPS guidance, revenue growth drivers, and operational efficiencies.

Medtronic reports solid Q1 results, raises guidance for fiscal '25

Medtronic's Q1 2025 performance reflects steady revenue growth and increased EPS, driven by strong performances in key business segments and global markets.
The company's focus on innovation, strategic partnerships, and diversified revenue streams positions it well for future growth and market expansion.
While challenges exist in maintaining growth momentum and navigating market complexities, Medtronic's raised guidance and growth expectations signal confidence in its ability to drive top-line growth and restore earnings power.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Intersect ENT

DUBLIN and MENLO PARK, Calif., Aug. 6, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced that it has entered into a definitive agreement with Intersect ENT (NASDAQ: XENT), a global ear, nose, and throat (ENT) medical technology leader dedicated to transforming patient care, in which Medtronic will acquire all outstanding shares of Intersect ENT for $28.25 per share in an all-cash transaction implying an enterprise value of approximately $1.1 billion.

Medtronic to Acquire Intersect ENT

Apple

AbbVie

Abbott Labs

Blackrock Inc

Disney

Global X SuperDividend US ETF

Amplify CWP Dividend & Option Income ETF

Cohen & Steers Closed-End Opportunity Fund

Corning

Home Depot

Xtrackers USD High Yield Corporate Bond ETF

iShares International Select Dividend ETF

JPMorgan Chase & Co

Mastercard

Global X MLP ETF

Altria

Microsoft

NIKE

Realty Income Corp

Global X U.S. Preferred ETF

Invesco NASDAQ Next Gen 100 ETF

Invesco Nasdaq 100 ETF

iShares Mortgage Real Estate ETF

Starbucks

My Dividend Growth Portfolio July Update: $500K Across 32 Holdings, 3 Buys, And 2 Sells

Accenture Plc

Automatic Data Processing

CME Group

Costco

Cisco Systems

General Dynamics

Honeywell

Intel

Johnson & Johnson

Eli Lilly

Lockheed Martin

Merck

PepsiCo

Procter & Gamble

Stryker

Texas Instruments

Union Pacific

Visa

Walmart

This article updates one published by David Van Knapp in June 2020.

The Highest Quality Dividend Growth Stocks

DUBLIN, July 29, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced the first gynecological (GYN) procedures with the Hugo™ robotic-assisted surgery (RAS) system. The six cases included hysterectomies and myomectomies performed by Salomón Zebede, M.D.

First Gynecological Procedures Performed with Medtronic Hugo™ Robotic-Assisted Surgery System

The FDA has cleared Medtronic Plc's (NYSE: MDT) two AccuRhythm AI algorithms for use with the Linq II ICM. AccuRhythm AI applies artificial intelligence to heart rhythm event data collected by the Linq II insertable cardiac monitor (ICM) to improve the information provided to physicians for better diagnoses and treatments for abnormal heart rhythms.

Medtronic's AI Algorithms For Cardiac Monitoring Scores FDA Approval

AI Algorithms Enhance LINQ II™ Insertable Cardiac Monitor Diagnostic Accuracy for Improved Management of Patients DUBLIN, July 28, 2021 /PRNewswire/ -- Medtronic plc (NYSE:MDT), the global leader in medical technology, today announced U.S. Food and Drug Administration (FDA) clearance for two AccuRhythm™ AI algorithms for use with the LINQ II™ insertable cardiac monitor (ICM). AccuRhythm AI applies artificial intelligence (AI) to heart rhythm event data collected by LINQ II, improving the accuracy of information physicians receive so they can better diagnose and treat abnormal heart rhythms.

Medtronic Announces FDA Clearance and Results of Artificial Intelligence Algorithms for Cardiac Monitoring

The medical device company's Hugo robotic-assisted surgery (RAS) system may end up playing a significant role in its growth.

Could Medtronic's Surgical Robotics Business Be a Growth Catalyst?

Medtronic's (MDT) newly-launched Prevail DCB demonstrates impressive safety and drug deliverability, utilizing a rapid absorption drug to treat patients with coronary artery disease.

Medtronic (MDT) Introduces New Drug Coated Balloon Catheter

Becton, Dickinson and Co.

Cardinal Health

You can combine high-quality companies with mega-trends that are favorable for long-term growth with these dividend healthcare stocks. The post 3 Healthcare Stocks for Dividend Growth appeared first on InvestorPlace.

3 Healthcare Stocks for Dividend Growth

Medtronic plc (NYSE: MDT) has announced new data from the WRAP-IT study published in Heart Rhythm. The study evaluated Tyrx absorbable antibacterial envelope, an absorbable, single-use device that holds a cardiac implantable electronic device or implanted neurostimulator.

Medtronic's Antibacterial Envelope Effective In Reducing Infections In Cardiac Device Patients With Hematomas

DUBLIN, July 26, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced new data from the landmark WRAP-IT study published in Heart Rhythm, demonstrating a significantly lower infection risk for patients who develop hematomas after cardiac implantable electronic devices (CIEDs) when the TYRX™ Absorbable Antibacterial Envelope (TYRX Envelope) is used at implant. The analysis showed an 82% reduction in major CIED infections among patients with the TYRX Envelope who developed hematomas compared to patients in the control group who developed hematomas.

Medtronic TYRX™ Absorbable Antibacterial Envelope Is Effective at Reducing Infections in Cardiac Device Patients with Hematomas

Medtronic Prevail DCB™ Designed to Treat Complex Lesions with Superior Deliverability, Rapid Absorption of Paclitaxel DUBLIN, July 26, 2021 /PRNewswire/ -- Medtronic plc (NYSE: MDT), the global leader in medical technology, today announced the launch of the Prevail™ drug coated balloon (DCB) Catheter in Europe following CE (Conformité Européene) mark. The newest coronary DCB on the market, the Prevail DCB is used during percutaneous coronary intervention (PCI) procedures to treat narrowed or blocked coronary arteries in patients with coronary artery disease (CAD).

Medtronic Launches Newest-Generation Drug Coated Balloon Catheter in Europe for Treatment of Coronary Artery Disease

A. O. Smith

Hormel Foods

NextEra Energy

Sherwin-Williams

S&P Global

Target

V.F.

If you're looking for dividend stocks to own from the S&P 500, these 10 Dividend Aristocrats are doing a lot better than most. The post The 10 Best Dividend Income Growers in the S&P 500 appeared first on InvestorPlace.

The 10 Best Dividend Income Growers in the S&P 500

Recent integration of Medtronic's (MDT) Hugo RAS System at UC CHRISTUS is intended to support the teaching institution's new robotic surgery program.

Medtronic's (MDT) Hugo RAS System Now Available at UC CHRISTUS

Cummins

Deutsche Telekom AG

Philip Morris

Sinclair Inc

Siemens AG

Toyota Motor

Vivendi SE

Vanguard Real Estate ETF

Woodward

July 19, 2021, Barron's-Weekly published their annual mid-year Roundtable picks from 10 investment experts. Of 42 selected, 21 pay dividends. These are "Barron's Mid-Year21," or BMY21. The top-10 BMY21 showed net gains ranging from 9.11%-38.34% by DTEGY, WWD, BDX, PM, MDT, TM, SBGI, CNHI, VIVHY, and SIEGY. Communications and Industrial sectors led; Materials went missing.

Barron's 42 Mid 2021 RoundTable Picks Show 21 With Dividends And 4 With Ideal Returns

News for Medtronic Stock (MDT)